|
Indian Pediatr 2020;57: 407-410 |
|
Coronavirus Vaccine: Light at the End of the
Tunnel
|
Krishna M Ella and V Krishna Mohan
Bharat Biotech International Limited, Genome Valley,
Shamirpet, Hyderabad, Telangana, India. Address for
correspondence: V Krishna Mohan, Executive Director, Bharat
Biotech International Limited, Genome Valley, Shamirpet,
Hyderabad, Telangana, India.
Email:
[email protected]
Published
online: April 15, 2020.
PII:
S097475591600163
|
The world is currently facing an
unprecedented global pandemic caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). Predicting the next source of
the pandemic can be very challenging. As vaccination is the best
way to prevent an infectious disease, the development of an
effective vaccine against SARS-CoV-2 can not only reduce the
morbidity and mortality associated with it, but can also lessen
the economic impact. As the traditional method of vaccine
development takes many years for a vaccine to be available to the
society, the vaccine development for SARS-CoV-2 should be speeded
up using a pandemic approach with fast-track approvals from the
regulatory authorities. Various challenges associated with
developing a vaccine during the pandemic such as technological
hurdles, clinical development pathways, regulatory issues, and
support from global funding agencies are expressed here.
Keywords: COVID-19, Immunization, Pandemic,
Prevention, SARS-CoV-2.
|
Many cases of respiratory illness started appearing in
the month of December, 2019 in Hubei Province, China [1].
The microorganism responsible for this illness was
subsequently discovered as coronavirus, and later
categorized as genetically related to coronavirus (SARS-CoV)
that was responsible for the severe acute respiratory
syndrome (SARS) which occurred in 2003. This new virus was
named as Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) and the disease was designated as Coronavirus
disease 2019 (COVID-19) by World Health Organization (WHO)
[2,3].
Structural analyses have shown that this
novel virus uses host cell receptor known as
Angiotensin-Converting Enzyme-2 for its binding [4].
Transmission dynamics confirmed that reproductive number
(R0, which signifies the number of people who can get
infected from one contagious person) of SARS-CoV-2 can be in
the range of 2–3, and thus has the potential to spread
rapidly [5]. Based on the clinical and epidemiological data
from the Chinese health authorities, clinical manifestations
of the disease by severity have shown that mild cases occur
in 81% of cases, severe disease is seen in 14% of cases and
critical disease has occurred in 5% of cases [6].
Considering the infectivity and the severity of COVID-19,
vaccines and therapeutics to tackle this deadly disease are
the greatest need of the hour.
Can We Predict
the Next Pandemic?
Global pandemic is a
major public health concern. Modern means of travel and the
volume of travel make it easier for any virus to rapidly
spread across the world. Pandemic is a once-in-a-lifetime
low-probability event but a high-cost problem that should
not be ignored. The next pandemic was anticipated to be a
more virulent form of influenza but the world is currently
in the midst of a novel coronavirus pandemic.
Though Middle East Respiratory Syndrome (MERS) and SARS were
featured in the WHO’s list of critical infectious diseases
in 2018, it was not anticipated to cause a global disease
within a short span of time [7]. Such is the
unpredictability of a global pandemic that the world is
currently facing.
THE NEED FOR A COVID-19
VACCINE
As the infectivity of the SARS-CoV-2
virus is very high compared to other corona viruses reported
so far, an effective vaccine is the best way to contain the
rapidly escalating proliferation of this infection. Although
the mortality rate is lower compared to other similar viral
respiratory diseases such as Middle East Respiratory
Syndrome Coronavirus (MERS-CoV), the magnitude of the
infection caused by SARS-CoV-2 is severe and higher, to a
large extent, leading to increased number of deaths
worldwide. SARS-CoV-2 infection has the potential to
become a seasonal disease like influenza and persist with
humanity in the future [8]. An effective vaccine can help in
reducing the rate of infection, and can significantly reduce
the morbidity and mortality of COVID-19. Vaccine can also
decrease the probability of resurgence of the disease and
its future impact. The implementation of an effective
vaccination is the only way to moderate the economic burden
of this unprecedented pandemic.
SPEEDING-UP
VACCINE DEVELOPMENT DURING PANDEMIC
There is
an urgent need to expedite the development of COVID-19
vaccine. The vaccine industry was able to develop H1N1
vaccine fairly rapidly because the technology and
regulations were already in place to develop influenza
vaccine. Global experiences with influenza vaccines have
outlined the urgency for investing in modern technologies
for faster vaccine development as well as increasing the
scale of production. Customizing these technologies to
various other viruses can speed up vaccine development
during a pandemic.
Organizations such as Coalition
for Epidemic Preparedness Innovation (CEPI), an innovative
global partnership between public and private organizations
are striving to quicken vaccine development for various
potential and critical diseases, as well as facilitate
uniform availability of these life-saving vaccines. CEPI
aims to develop vaccines for various pathogens till phase 2a
stage, which can be expedited to full-scale development
during future outbreaks [9].
CEPI and the World Bank
organized a conference on the three main imperatives for
COVID-19 vaccine effort: speed, manufacture and deployment
at scale, and global access, which has ultimately led to the
formulation of COVID-19 Vaccine Development Taskforce [10].
Multiple Technology Platforms Under Evaluation
The wide ranges of technologies that are being
developed for SARS-CoV-2 include nucleic acids, protein
subunit, replicating viral vector, non-replicating viral
vector, and inactivated virus approaches. Newer approaches
based on nucleic acids such as DNA or mRNA can facilitate
potentially rapid production, as they do not need
fermentation [9]. For some platforms, adjuvants could
improve the immune responses with lower doses thus ensuring
vaccination of larger populations without any reduction in
efficacy [11]. Currently, several platforms are being
developed and the list of SARS-CoV-2 vaccine candidates in
development is given in Web Table 1.
Challenges in COVID-19 Vaccine Development
The development of a vaccine for SARS-CoV-2 can cause
distinct challenges.
• Developing a viable immunogen
using the various proteins of SARS-CoV-2 such as S protein,
N protein, M protein is the initial challenge.
•
Development of successful animal model for COVID-19 may be
challenging although two animal models; one hACE2 transgenic
mice model and another, primate macaques model have been
successfully developed. This may be due to the highly
infectious and pathogenic nature of the virus [12].
•
Vaccine development is a lengthy process, starting from
product development to the competition of the phase III
clinical trial before marketing the vaccine, which can take
several years, usually 10 to 20 years.
• Preclinical
experience with other SARS vaccine candidates has created
red flags about worsening of the disease, which may be
attributed to antibody-dependent enhancement.
•
Correlates of protection are not known.
• Planning
and coordinating clinical trials in these emergency-like
situations can be difficult, both for predicting the trial
sites for outbreak as well as ensuring the site’s
preparedness.
• In a high-mortality situation such
as COVID-19 pandemic, regulators may not accept
conventionally designed clinical trials such as comparison
with a placebo arm.
• Viral mutation may lead to
different subtypes thus causing difficulty in vaccine
design.
• Vaccines are generally manufactured using
Good Manufacturing Practices (GMP) to ensure that quality is
controlled and consistency is maintained. For many vaccine
candidates in the current pipeline for SARS-CoV-2, these GMP
processes need to be developed, which can be time consuming.
• For vaccines that will be developed with novel
technologies, GMP needs to be developed from the beginning,
thus adding to the financial burden and delaying the
production of vaccines.
• Issues related to vaccine
ownership, funding, pricing and supply chain, and the
coordinated administration strategy can pose significant
barriers.
Role of Regulatory Bodies
The traditional vaccine development process follows
various phases such as product development, pre-clinical,
clinical trial phases (phase I, II, and III) before the
vaccine gets regulatory approval for marketing although
phase IV and post-marketing surveillance studies are
conducted after marketing the product. This traditional
approach is time consuming and not feasible to follow during
the pandemic. Keeping greater benefit of the
vaccine for the societal need, vaccine development using
pandemic approach will be the best approach for rapid
development of vaccines as shown in Fig. 1. This type of
innovative approach can save the time spent in pre-clinical
and clinical trial phases. The regulators should consider
this approach for faster approval of vaccines.
Funding for Vaccine Development During Pandemics
Vaccine development during a pandemic should be
considered as a global health emergency and not as any
specific disease related issue, which is a prerogative of
vaccine manufacturers. Public funding for vaccine
development should be the top priority as any vaccine
development, particularly during a pandemic can be a very
risky investment, and public funding can reduce the
potential risk for vaccine manufacturers, especially in the
low and middle income countries.
Pioneering finance
mechanisms such as the International Finance Facility for
Immunization (IFFIm) that have been successful in the past
should be used to fund the development of COVID-19 vaccines
[10]. Global Alliance for Vaccines and Immunizations (GAVI)
board members also expressed support for the use of GAVI’s
innovative financing instruments, such as its IFFIm and
GAVI’s Advance Market Commitment to accelerate vaccine
development and access where needed [13].
There
should be a global consensus and urgency for the development
of a pandemic vaccine, at both national and international
level to ensure that the vaccines are available and
affordable to those who need them the most [14].
Challenges After the Vaccine is Developed
• For novel platform technologies, large-scale
manufacturing can pose a significant financial risk as these
facilities necessitate huge investments. • High-income
countries can procure large doses of vaccine for their own
population, creating disparities in the global supply and
demand. • High risk populations should be identified
through epidemiological and serological studies and vaccine
delivery should be prioritized. This can halt the spread of
the disease. • As SARS-CoV-2 is a newer disease without
adequate exposure in the population, any new vaccine may
probably necessitate more than one dose of the vaccine and
protective immunity is usually achieved after the second
dose. Massive effort will be needed to ensure vaccine
distribution and administration. • There can be a
scenario, albeit low-probability, where the pandemic threat
has been abruptly curtailed. In such cases, vaccine
development should be continued for potential vaccine
candidates to restrict future threats.
FUTURE
OUTLOOK
The global vaccine development
efforts for COVID-19 pandemic are unparalleled. In the
current scenario, there is an indication that vaccine could
be available as early as 2021. This would be an
extraordinary shift from the usual vaccine development
timeframe which can range between 10-20 years. A new virus
target and newer technologies can multiply the vaccine
development risks, and dictates meticulous evaluation of
safety and efficacy at every stage of vaccine development.
Robust coordination between vaccine manufacturers,
regulatory authorities, public health authorities and
governments is essential to make sure that potential vaccine
candidates are fast-tracked for approval, manufactured and
distributed seamlessly, particularly for low-income
countries.
Considering the economic impact that
COVID-19 has already caused in the initial 3-4 months of
this global calamity, it is worthwhile to start investing in
vaccines against emerging viruses, including neglected
diseases, which can potentially cause significant human
deaths and also impact the global economy. Global pandemics
are inevitable. There should be strategically prepared
protocols and emergency plans to develop vaccines in months
rather than years. Lessons learned in managing the COVID-19
pandemic should pave the way for creating better roadmaps to
face the next pandemic.
Acknowledgements: Shashi
Kanth Muni (Associate Medical Director, Bharat Biotech) and
Dr. Sapan Kumar Behera (Senior Manager, Bharat Biotech)
supported the preparation of this manuscript.
Funding: None; Competing interests: KME is Chairman and
Managing Director and VKM is Executive Director of Bharat
Biotech International Limited, which is a vaccine
manufacturer.
REFERENCES
1.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical
features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet. 2020;395:497–506.
2. Lu R, Zhao
X, Li J, Niu P, Yang B, Wu H, et al. Genomic
characterisation and epidemiology of 2019 novel coronavirus:
implications for virus origins and receptor binding.
Lancet.2020;395:565-74.
3. Gorbalenya AE, Baker SC,
Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe
acute respiratory syndrome-related coronavirus: the species
and its viruses –a statement of the coronavirus study group.
BioRxiv. 2020;20200207: 937862.
4. Wan Y, Shang J,
Graham R, Baric RS, Li F. Receptor recognition by novel
coronavirus from Wuhan: An analysis based on decade-long
structural studies of SARS. J Virol. 2020.Available from:
https://jvi.asm.org/content/jvi/94/7/e00127-20.full.pdf.
Accessed April 10, 2020.
5. Li Q, Guan X, Wu P, Wang
X, Zhou L, Tong Y, et al. Early transmission dynamics in
Wuhan, China, of novel coronavirus-infected pneumonia. N
Engl J Med. 2020.Available from:
https://www.nejm.org/doi/full/10.1056/NEJMoa2001316.Accessed
April 11, 2020.
6. Cascella M, Rajnik M,
CuomoA,Dulebohn SC, Di Napoli R. Features, evaluation and
treatment coronavirus (COVID-19). Available
from:https://www.ncbi.nlm.nih. gov/books/NBK554776/.Accessed
April 11, 2020.
7. WHO 2018 Annual review of diseases
prioritized under the Research and Development Blueprint.
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf.
Accessed April 11, 2020.
8. Zhang J, Zeng H, Gu J, Li
H, Zheng L, Zou Q. Progress and prospects on vaccine
development against SARS-CoV-2. Vaccines (Basel).
2020;8:153. Available
from:https://www.mdpi.com/2076-393X/8/2/153/htm.Accessed
April 10, 2020.
9. Lurie N, Saville M, Hatchett R,
Halton J. Developing Covid-19 vaccines at pandemic speed. N
Engl J Med. 2020 Mar 30. [Epub ahead of print]. Available
from: https://www.nejm.org/doi/full/10.1056/NEJMp2005630.
Accessed April 12, 2020.
10. Yamey G, Schäferhoff M,
Hatchett R, Pate M, Zhao M, McDade KK. Ensuring global
access to COVID-19 vaccines. Lancet. 2020.Available from:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30763-7/fulltext.Accessed
April 11, 2020.
11. Le TT, Andreadakis Z, Kumar A,
Román RG, Tollefsen S. The COVID-19 vaccine development
landscape. Nature Rev Drug Disc. 2020.Available from:
https://www.nature.com/articles/d41573-020-00073-5.Accessed
April 11, 2020.
12. Dhama K, Sharun K, Tiwari R,
Dadar M, Malik YS, Singh KP. COVID-19, an emerging
coronavirus infection: Advances and prospects in designing
and developing vaccines, immunotherapeutics, and
therapeutics. Hum Vaccin Immunother. 2020 Mar 18 [Epub ahead
of print]. Available from:
https://www.tandfonline.com/doi/full/10.1080/
21645515.2020.1735227.Accessed April 12, 2020.
13.
Global Alliance for Vaccines and Immunisation (Gavi.org)
Media room.Available
from:https://www.gavi.org/news/media-room/gavi-board-calls-bold-engagement-respond-covid-19.
Accessed April 12, 2020. 14. Fedson DS. Vaccine
development for an imminent pandemic: Why we should worry,
what we must do. Human Vacc. 2006;2:38-42.
|
|
|
|